clinical trial · NCT05251727
Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients
Chemotherapy-induced Peripheral Neuropathythrombomodulin alfaPlacebo
brief summary
To evaluate the safety and tolerability of ART-123 in patients with metastatic colorectal cancer who receive oxaliplatin-containing chemotherapy and bevacizumab
started
Mar 24, 2022
primary completion
Jun 5, 2024
completion
Jun 5, 2024
last updated
Aug 19, 2024
detailed description
To compare the safety and tolerability of ART-123 to placebo in patients with metastatic colorectal cancer who receive oxaliplatin-containing chemotherapy and bevacizumab
official title
Double-blind, Placebo-controlled, Randomized, Dose-escalating, Multi-center, Phase 1 Study to Assess the Safety and Tolerability of ART-123 With Leucovorin/5-fluorouracil/Oxaliplatin and Bevacizumab in Metastatic Colorectal Cancer Patients
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol